Company Shin Nippon Biomedical Laboratories, Ltd.
Equities
2395
JP3379950003
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,502 JPY | +1.49% | +5.55% | -11.54% |
Business Summary
Number of employees: 1,344
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Contract Research Organization
95.4
%
| 16,944 | 95.5 % | 23,924 | 95.4 % | +41.20% |
Medipolis
2.4
%
| 528 | 3.0 % | 601 | 2.4 % | +13.79% |
Other
2.2
%
| 264 | 1.5 % | 549 | 2.2 % | +107.67% |
Translational Research
0.1
%
| 12 | 0.1 % | 16 | 0.1 % | +36.63% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
73.8
%
| 14,657 | 82.6 % | 18,515 | 73.8 % | +26.32% |
United States
15.3
%
| 1,934 | 10.9 % | 3,843 | 15.3 % | +98.76% |
Other
10.9
%
| 1,158 | 6.5 % | 2,733 | 10.9 % | +136.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 02-04-30 |
Terumasa Hirai
CMP | Compliance Officer | - | 84-03-31 |
Shunji Haruta
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-31 |
Ken Takanashi
COO | Chief Operating Officer | 59 | 02-11-30 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 17-03-31 |
Kyomi Nagatoshi
IRC | Investor Relations Contact | - | 02-01-31 |
Hiroyuki Izumi
PRN | Corporate Officer/Principal | - | 92-03-31 |
Masakazu Suda
AUD | Comptroller/Controller/Auditor | 62 | 90-07-31 |
Toshihiko Makino
AUD | Comptroller/Controller/Auditor | - | 05-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ichiro Nagata
BRD | Director/Board Member | 38 | 17-03-31 |
Sales & Marketing | 64 | 02-10-31 | |
Ken Takanashi
COO | Chief Operating Officer | 59 | 02-11-30 |
Corporate Officer/Principal | 56 | 99-05-31 | |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 02-04-30 |
Hideshi Tsusaki
PRN | Corporate Officer/Principal | 57 | 96-03-31 |
Director/Board Member | 65 | 15-05-31 | |
Director/Board Member | 68 | 15-05-31 | |
Tsuyoshi Hanada
BRD | Director/Board Member | - | 20-06-25 |
Keiko Toya
BRD | Director/Board Member | 60 | 21-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 41,632,400 | 20,315,331 ( 48.80 %) | 469 ( 0.001127 %) | 48.80 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
WAVE LIFE SCIENCES LTD. 100.00% | 3,901,348 | 100.00% | 24,071,317 $ |
TMS CO., LTD. 3.56% | 1,433,320 | 3.56% | 2,661,231 $ |
400 | 0.00% | 4,012 $ |
Company contact information
Shin Nippon Biomedical Laboratories, Ltd.
St. Luke's Tower, 28/F 8-1 Akashi-cho
104-0044, Tokyo
+81 9 9294 3389
http://www.snbl.co.jpSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.54% | 397M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- 2395 Stock
- Company Shin Nippon Biomedical Laboratories, Ltd.